Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Pfizer said it will discontinue gene therapy Beqvez (fidanacogene elaparvovec-dzkt), an approved hemophilia B treatment.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Columnist Jennifer Lynne assesses the effects of Pfizer's decision to halt production of its hemophilia B gene therapy, Beqvez.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

STORY HIGHLIGHTS Pfizer discontinues Beqvez gene therapy due to lack of demand. Company invested heavily in North Carolina gene therapy facilities. Pfizer maintains large manufacturing presence in ...

Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...